Safety and Efficacy of the CRE8 Stent for the Treatment of De Novo Coronary Artery Lesions

Coronary Artery Disease Clinical Trial

Official title:

A Prospective, Multi-center, Randomized Controlled Trial Evaluating the Safety and Efficacy of the CRE8 Sirolimus-Eluting Stent Versus the RESOLUTE Zotarolimus-Eluting Stent in the Treatment of Patients With De Novo Coronary Artery Lesions

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02360423
• Other study ID #: CRE8-China-RCT
• Status: Recruiting
• Phase: Phase 3
• First received: February 3, 2015
• Last updated: March 23, 2015
• Start date: November 2014
• Est. completion date: April 2021

Study information

• Verified date: March 2015
• Source: CID S.p.A.
• Contact: Shubin Qiao, MD
• Phone: +86 13701237893
• Email: qli[@]ccrfmed.com;qsbfw[@]sina.com
• Is FDA regulated: No
• Health authority: China: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, efficacy and deliverability of the CRE8 sirolimus-eluting stent and the RESOLUTE zotarolimus-eluting stent in the treatment of patients with de novo coronary artery lesions.

Description:

This study consists of a randomized controlled cohort and a long stent observational cohort. The randomized controlled trial is a prospective, multi-center, non-inferior, randomized controlled trial. The control device (RESOLUTE zotarolimus-eluting stent) used in this trial was provided by Medtronic. RESOLUTE zotarolimus-eluting stent has been already approved by China Food and Drug Administration (CFDA) in 2009 and become commercially available in Chinese market. 400 patients enrolled in this trial will be randomly assigned to CRE8 group (n=200) and RESOLUTE group (n=200) in a 1:1 ratio. The long stent observational trial plans to enroll 30 consecutive patients. Patients in the observational cohort will receive the long CRE8 stent with length 38mm.All 430 patients will be required to receive clinical follow-up at 1 month, 6 months, 9 months, 12 months and annually up to 5 years after the procedure, and angiographic follow-up at 9 months after the procedure. The primary endpoint is in-stent LLL at 9 months after the procedure, and the secondary endpoints are device success rate, device-oriented cardiovascular composite endpoint, patient-oriented cardiovascular composite endpoint and stent thrombosis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 430
• Est. completion date: April 2021
• Est. primary completion date: October 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

Inclusion criteria for randomized cohort:

• Age =18 years and = 75 years, male or female without pregnancy;

• Patients with clinical evidence of asymptomatic heart disease, stable or unstable angina, or old myocardial infarction;

• De novo lesions of native coronary arteries (lesions number = 2);

• Target vessel diameter between 2.25 and 4.0 mm and target lesion length = 27mm by visual estimation;

• Target lesion diameter stenosis = 70% by visual estimation;

• Each target lesion is permitted to implant only one stent at most, except bailout stent;

• Patients is eligible for percutaneous coronary intervention (PCI) and is an acceptable candidate for surgical revascularization (CABG);

• Patients with left ventricular ejection fraction =40%;

• Patients who can understand the nature of the study, agree to participate and accept angiographic and clinical follow-up, and have provided written informed consent.

Inclusion criteria for the long stent observational cohort:

• Age =18 years and = 75 years, male or female without pregnancy;

• Patients with clinical evidence of asymptomatic heart disease, stable or unstable angina, or old myocardial infarction;

• De novo lesions of native coronary arteries (lesions number = 2);

• Target lesion diameter stenosis = 70% by visual estimation;

• At least one target lesion with reference vessel diameter between 2.5mm and 4.0mm and requires 38mm stent exists;

• Patients is eligible for percutaneous coronary intervention (PCI) and is an acceptable candidate for surgical revascularization (CABG);

• Patients with left ventricular ejection fraction =40%;

• Patients who can understand the nature of the study, agree to participate and accept angiographic and clinical follow-up, and have provided written informed consent.

Exclusion Criteria:

• Patients with acute myocardial infarction (AMI) within one week;

• Chronic total occlusion lesion (TIMI flow 0 before procedure), Left main disease and/or triple-vessel lesion that might require treatment, bifurcation lesions with a side branch diameter >2.5mm or graft lesions;

• Heavily calcified or tortuous lesions which cannot be successfully pre-dilated, and lesions which are not suitable for stent delivery and deployment;

• In-stent restenosis;

• Thrombotic lesion;

• Patients who had received any other stent in the past one year;

• Patients with acute or chronic renal dysfunction (defined as creatinine greater than 2.0 mg/dl);

• Patients with cardiogenic shock, acute infection, known bleeding or coagulation disorder, or with a history of active gastrointestinal bleeding, ulcer, cerebral hemorrhage or subarachnoid hemorrhage and stroke within 6 months;

• Patients who allergic to aspirin, clopidogrel, ticagrelor, ticlopidine, heparin, contrast agent, sirolimus, zotarolimus, polymer, Co-Cr alloy, or with contraindication to aspirin or clopidogrel or ticagrelor;

• Patients with life expectancy less than 1year;

• Patients who had participated in another investigational drug or device trial that has not completed the primary endpoint;

• Patient is in the opinion of the investigator, unable to comply with the requirements of the study protocol;

• Patients who had underwent heart transplant surgery.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Coronary Artery Disease
• Coronary Disease
• Myocardial Ischemia

Intervention

Device:
• CRE8 sirolimus-eluting stent
The CRE8 stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium alloy and is coated with i-carbofilm.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
• RESOLUTE zotarolimus-eluting stent
The RESOLUTE stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium tungsten alloy. It has been approved by CFDA in 2009 and commercially available in Chinese market

Locations

Country	Name	City	State
China	Fuwai Hospital,National Center for Cardiovasular disease	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
CID S.p.A.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	In-stent late lumen loss (LLL)		9months after the procedure	No
Secondary	In-stent, proximal stent edge, distal stent edge and In-segment binary restenosis rate		9months after the procedure	No
Secondary	In-segment late lumen loss (LLL)		9months after the procedure	No
Secondary	Target lesion failure (TLF) rate		1month, 6months, 9months, 12months and annually up to 5 years follow-up	Yes
Secondary	Number of participants with stent thrombosis per ARC definition		1month, 6months, 9months, 12months and annually up to 5 years follow-up	Yes
Secondary	The patient-oriented composite endpoint includes all-cause death, all MIs, or any revascularizations		1month, 6months, 9months, 12months and annually up to 5 years follow-up	Yes
Secondary	device and lesion success rates		immediately after the procedure	No
Secondary	clinical success rate		7 days after the procedure	No